

Palbociclib PALOMA-1/TRIO-18

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Palbociclib PALOMA-1/TRIO-18

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.

Experimental Arm: Palbociclib + Letrozole

Control Arm: Letrozole

